Thailand's drug agency signs cooperation memorandum with Sandoz

The partners will assess demand, supply and access to biosimilars

The signing took place at the Ministry of Public Health in Nonthaburi, with the health minister attending. The government's account presents the agreement as part of Thailand's effort to improve pharmaceutical supply planning and build capability within the country's healthcare industry.

Biosimilars are biological medicines developed to be highly similar to an already authorised reference product in quality, safety and efficacy. They can be relevant to treatments that patients may need over extended periods. Establishing similarity and obtaining the necessary approvals are distinct steps; the memorandum itself is not a medicine approval.

The proposed cooperation includes assessing patient needs and expected demand, reviewing supply arrangements and exploring the regulatory and market-access work needed for biosimilars. Those details are more relevant to someone managing ongoing treatment than the signing ceremony alone. Reliable procurement could eventually reduce interruptions, although no such outcome has yet been demonstrated by this agreement.

For practical context, see Thailand economy and finance. This development also connects with Thailand Tightens State Data Security After DLT Incident.

Local packaging is being explored, with no product launch announced

Thailand also wants more pharmaceutical activity to take place domestically. The framework described in public statements includes possible local filling and packaging operations, alongside knowledge-sharing and other capacity-building work. None of that establishes that a plant has opened or that Sandoz and GPO have committed to a particular local production schedule.

Nor did the October 14 announcements specify a list of medicines that would become available, a delivery timetable or retail prices. Greater affordability is an objective of the cooperation, not a confirmed saving for patients today. This distinction is particularly important for residents comparing the cost of long-term healthcare in Thailand.

Access will still depend on the actual product, its Thai regulatory status, the hospital or pharmacy supplying it and the patient's payment arrangements. Foreign residents should not assume that the agreement changes their insurance benefits or eligibility for publicly funded treatment. Anyone considering a change to a prescribed biological medicine should discuss that decision with their treating clinician.